Years on First-Line Therapy: A New Reality for Metastatic Breast Cancer

With response rates approaching 85% and unprecedented durability, first-line HER2-positive metastatic breast cancer treatment is entering a new era.

What once seemed impossible — years of disease control on initial therapy — is now becoming reality.